Chimeric antigen receptor (CAR) T cells can be remarkably effective in treating leukemias and lymphomas, but there are no successful immunotherapies for neuroen
Chimeric Therapeutics Ltd (ASX:CHM) has signed a sponsored research agreement with the University of Pennsylvania to support the continued research and.
)
Chimeric Therapeutics licenses novel CAR T cell therapy with “transformative potential” from the University of Pennsylvania
Thanks to an exclusive licensing agreement with “a powerhouse in CAR T innovation”, Chimeric believes it is a step closer to bringing cell therapy to life for cancer patients. Chimeric Therapeutics will develop and commercialise a novel immunotherapy from one of the world’s pre-eminent cell therapy centres.
Chimeric Therapeutics Ltd has licensed a novel cancer therapy for solid tumours from a world-renowned cell therapy centre.
Through an agreement with the University of Pennsylvania, the ASX-listed biotech will exclusively develop and commercialise the CDH17 chimeric antigen receptor T cell (CAR T) therapy.